Request Appointment
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Segal
Dr. Neil Segal is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from University of the Witwatersrand and has been in practice 21 years. Dr. Segal accepts several types of health insurance, listed below. He is one of 525 doctors at Memorial Sloan Kettering Cancer Center and one of 91 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
NYU Grossman School of MedicineResidency, Internal Medicine, 2002 - 2005
University of the WitwatersrandClass of 1996
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2027
NY State Medical License 2007 - 2027
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
- CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
Clinical Trials
- Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer Start of enrollment: 2009 Jun 01
- Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2010 Dec 01
- Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- Acquired high tumor mutational burden and activity of immunotherapy after targeted therapy in microsatellite stable colorectal cancer.Celine Yeh, Oliver Artz, Haochen Zhang, Elias-Ramzey Karnoub, Peter Ntiamoah
Clinical Cancer Research. 2025-10-30 - The value of MRI and flexible sigmoidoscopy in detecting tumor regrowth in watch and wait rectal cancer patients undergoing active surveillance after total neoadjuvant...Trevor M Yeung, Roni Y Rosen, Aron Bercz, Hannah Williams, Dana Omer
Surgical Endoscopy. 2025-09-01 - 4 citationsInduction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer.Benoit Rousseau, Mitesh Patel, Oliver Artz, Georgios Vlachos, Shrey Patel
Cancer Cell. 2025-07-14
Lectures
- First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Immune Therapy: Why Don't We Have the KEY for VICTORy?2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
MSK Research Highlights, July 15, 2025July 15th, 2025- ASCO21 Preview - Equity: Every Patient. Every Day. EverywhereMay 27th, 2021
INNATE PHARMA : Data from Phase I of Monalizumab and Durvalumab in MSS-CRC at ASCO 2018September 12th, 2018
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOMultiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
